A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)

NCT01294709 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Angina Pectoris
Coronary Heart Disease
Calcitonin Gene-related Peptide Receptor

Interventions

DRUG: telcagepant
DRUG: Placebo to telcagepant

Sponsor

Merck Sharp & Dohme LLC